USFDA grants priority review to Merck’s sBLA for KEYTRUDA
The US Food and Drug Administration (FDA) has granted priority review for Merck’s supplemental biologics license application (sBLA) for KEYTRUDA (pembrolizumab) as adjuvant therapy for patients with renal